Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
US sanctions on Russian oil giants prompt major buyers like China and India to scale back imports, disrupting global energy markets.
Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
US sanctions on Russian oil giants prompt major buyers like China and India to scale back imports, disrupting global energy markets.